OSAKA — Matsushita Electric Industrial Co. and U.S. venture business Tensor Biosciences have signed an agreement to jointly develop and commercialize Brain-on-a-Chip drug discovery technology, the two companies said Tuesday.
The five-year agreement calls for combining advanced Matsushita instruments that enable the real-time study of activity patterns in living brain tissue with Tensor’s realistic brain models and associated drug tests.
Specifically, the joint work will focus on Tensor’s Brain-on-a-Chip platform of testing assays centered around Matsushita’s MED64 System, a multielectrode neurophysiology instrument for use in neurobiological research.
The two companies will test drugs for the treatment of neurological diseases such as depression and epilepsy.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.